NAD+ is often discussed alongside growth hormone-releasing compounds, such as Tesamorelin and Sermorelin, as well as research peptides like Selank. These compounds are frequently placed in broad categories such as „longevity” or „biohacking”, yet from a scientific perspective they differ significantly from one another.
Their chemical structures, biological mechanisms, clinical evidence base and regulatory status are not interchangeable. A reliable comparison should therefore be based on published studies concerning each compound rather than the marketing categories in which they are frequently grouped.
In this article, we compare NAD+ with peptide-based approaches such as Tesamorelin, examine whether these compounds have been studied together, and analyse the relative strength of the evidence supporting each of these approaches.
How does NAD+ compare with longevity-related peptide compounds, such as Tesamorelin?
The first major difference is the chemical structure.
NAD+ is a dinucleotide composed of two nucleotide units joined together: one containing nicotinamide and the other containing adenine, linked by phosphate groups [1]. It is not a peptide.
Tesamorelin, sermorelin, selank and other peptides are chains of amino acids linked by peptide bonds. They therefore belong to a fundamentally different category of molecules.
Tesamorelin is specifically a synthetic analogue of human growth hormone-releasing hormone, or GHRH, composed of 44 amino acids.
Its structure features a trans-3-hexenoic acid modification at the N-terminus. This modification helps protect the molecule from rapid enzymatic degradation and extends its circulation time compared to natural GHRH.
Tesamorelin works via a hormone-dependent receptor mechanism.
It binds to GHRH receptors on pituitary somatotroph cells and activates G-protein coupled signalling. This stimulates the pituitary gland to release endogenous growth hormone.
Tesamorelin does not therefore deliver growth hormone directly. Instead, it stimulates the body's own secretion of growth hormone, maintaining a more physiological, pulsatile secretion pattern than the direct administration of exogenous growth hormone.
NAD+ works via a completely different biological system.
It acts as an electron-carrying coenzyme in cellular energy metabolism and is also an essential substrate for enzymes, including sirtuins and PARPs [1,2].
Therefore, the two compounds differ not only in structure, but also in their fundamental biological role: tesamorelin acts via hormonal receptor signalling, whereas NAD+ participates directly in cellular metabolism and enzymatic activity.
Their clinical development history also differs significantly.
Tesamorelin was developed and studied for a specific medical problem: excess visceral adipose tissue associated with lipodystrophy in people living with HIV.
Two large, multicentre, randomised, double-blind, placebo-controlled Phase 3 studies included a total of 806 HIV-infected individuals on antiretroviral therapy with excess visceral adipose tissue in the abdomen. Participants were randomised in a 2:1 ratio to tesamorelin 2 mg daily or placebo [3].
The initial 26-week study included 412 participants and showed that tesamorelin significantly reduced visceral adipose tissue compared with placebo. A moderate improvement in triglyceride levels and trunk fat was also observed [3].
A pooled analysis of key studies showed that reductions in visceral adipose tissue could be sustained for up to 52 weeks with continued treatment. Subcutaneous abdominal adipose tissue was preserved, and improvements in body image and lipid parameters were also observed without clinically significant changes in glycaemic parameters [3,4].
NAD+ precursors have undergone a much broader, yet more exploratory, research path.
Instead of developing them for one clearly defined indication, NR, NMN and other NAD+-related approaches have been investigated in areas such as energy metabolism, lipid profile, blood pressure, physical performance, Parkinson's disease and peripheral artery disease [5,6].
However, this broader research programme did not lead to an FDA-approved indication comparable to the specific approval of tesamorelin in HIV-associated lipodystrophy.
Are NAD+ and GHRH analogue peptides sometimes combined?
NAD+ and GHRH-related compounds, such as Tesamorelin or Sermorelin, are sometimes offered together by longevity, wellness or peptide clinics.
NAD+ can be administered intravenously or by injection, whilst the peptide component forms part of a broader protocol involving several compounds. Such combinations are often presented in the context of cellular health, biohacking, longevity or body optimisation.
However, clinical practice and commercial availability must be distinguished from evidence derived from controlled clinical trials.
No published, controlled clinical trial has been identified that specifically tests NAD+ together with Tesamorelin as a single intervention.
Similarly, no dedicated study of the combination of NAD+ with sermorelin or another GHRH analogue has been identified.
Claims that the combination of these compounds provides a specific synergistic effect are therefore not currently based on direct data from research on such a combination.
Both classes of compounds do indeed have distinct mechanisms of action.
GHRH analogues act through receptor-mediated hormonal signalling involving the pituitary gland and the growth hormone axis, whereas NAD+ is involved in cellular energy metabolism and NAD+-dependent enzyme systems.
The lack of obvious mechanism overlap proves neither a harmful interaction nor a beneficial synergy.
It merely means that the compounds interact via different biological pathways, whereas the clinical effects of their simultaneous use remain insufficiently studied.
This situation is similar to other combinations of NAD+ with compounds such as NAC, berberine, resveratrol or omega-3 fatty acids, where there are distinct biological rationales, but dedicated human combination studies are limited or lacking.
Which approach currently has stronger research support?
The answer depends on the specific effect being assessed.
Regarding the FDA-approved indication, tesamorelin has a significantly stronger evidence base than NAD+.
Tesamorelin gained FDA approval in 2010 specifically for the reduction of excess visceral adipose tissue in HIV-infected adults with lipodystrophy.
The approval was based on two large, multicentre, randomised, double-blind, placebo-controlled phase 3 trials involving a total of 806 participants, along with safety data and data from extension studies up to 52 weeks [3,4].
Additional post hoc analyses and observational studies evaluated metabolic and cardiovascular outcomes in the same clinical population [7].
This constitutes a mature, FDA-assessed clinical evidence package for one clearly defined indication.
No NAD+ related supplement or therapy has attained a comparable body of evidence leading to FDA indication approval.
However, outside of the approved use of tesamorelin, the comparison looks different.
Tesamorelin is sometimes discussed or used outside of HIV-associated lipodystrophy for purposes such as general body composition improvement, anti-ageing effects, or other longevity-related goals.
Such uses are off-label and are not supported by the same evidence base that led to the approval of the medicine for its official indication.
A systematic review evaluating growth hormone axis therapies in HIV-associated lipodystrophy indicated that placebo-controlled data for these interventions focus mainly on the HIV lipodystrophy population in which they were studied [8].
Strong evidence regarding tesamorelin in this population should therefore not be automatically extrapolated to general claims concerning anti-ageing or body composition in individuals without HIV-associated lipodystrophy.
NAD+ precursors have a different evidence profile.
It was evaluated in a broader range of randomised, placebo-controlled trials involving general adult populations and several specific clinical groups.
For example, a 60-day NMN study with varying doses involving 80 healthy middle-aged and older adults showed a dose-dependent increase in NAD+ and an improvement in the 6-minute walk test score [5].
A meta-analysis of 40 human studies involving 14,750 participants showed that NAD+ precursors significantly reduced triglyceride, total cholesterol and LDL cholesterol levels [6].
These results do not establish an approved medical indication for NAD+ precursors, but they show that NAD+-related research encompasses a broader range of metabolic and physical performance outcomes in the general population than the evidence supporting the off-label use of Tesamorelin.
This distinction is therefore important.
For its specific approved medical use, tesamorelin has a significantly stronger evidence base, but this relates specifically to HIV-associated lipodystrophy.
In the case of broader exploratory studies concerning metabolic outcomes and physical fitness in the general adult population, NAD+ precursors have a larger and more diverse human research base, although without an FDA-approved indication.
Regarding broad claims about anti-ageing or life extension, none of these categories currently have strong direct evidence from human studies confirming an increase in human lifespan or a proven general anti-ageing effect.
How do these approaches differ in terms of their intended effect?
NAD+ and Tesamorelin are not directly competing versions of the same intervention.
Their biological mechanisms, regulatory status, studied populations and evaluated clinical outcomes differ significantly, which is why a straightforward comparison of the two compounds is less useful than comparing the quality of evidence for a specific purpose.
For HIV-associated lipodystrophy, tesamorelin has an FDA-approved indication supported by controlled phase 3 trials [3,4].
Clinical trials have also shown that the reduction in visceral adipose tissue depended on the continuation of treatment. Following the discontinuation of tesamorelin, the amount of visceral adipose tissue increased again, indicating that the effect was not a permanent change achieved after a single treatment cycle [3,4].
For general body composition, energy or anti-ageing applications in individuals without HIV-associated lipodystrophy, Tesamorelin is used off-label.
Evidence supporting such broader uses is considerably less well-established than the data regarding its approved use [8].
Research into NAD+ precursors concerns a different set of results.
They evaluated NAD+ biomarkers, lipid parameters, energy metabolism, physical fitness, and selected issues in specific disease states [5,6].
In this category, oral NR and NMN currently have a larger base of human clinical trials than many direct NAD+ delivery methods.
Combining NAD+ with Tesamorelin presents yet another issue.
As both compounds operate via different mechanisms, they can be treated as two separate interventions placed within the same protocol, rather than as different elements of a single fixed pharmacotherapy.
No dedicated combination study has shown that using them together provides a greater effect than using each of them independently.
Based on current evidence, such a combination should therefore not be described as a clinically validated „longevity stack” or an established synergistic protocol.
How do NAD+ and other peptides fit into this comparison?
Tesamorelin is particularly useful for comparison as it has undergone extensive clinical development and has an FDA-approved indication.
Other peptides frequently grouped together with NAD+ in the „longevity” or „biohacking” category may have a completely different level of evidence.
For example, sermorelin is also linked to the growth hormone-releasing hormone pathway and acts via GHRH receptors, which is why mechanistically it is much closer to tesamorelin than to NAD+.
Research peptides such as Selank belong to another, separate category and should not be assumed to have the same mechanism, clinical evidence base, or regulatory status as NAD+ or GHRH analogues.
Grouping these compounds together under a broad commercial category may therefore obscure important scientific differences.
The term „peptide” describes a structural class rather than a single shared mechanism of action. Different peptides can interact with completely different receptors and biological systems.
NAD+ does not belong to this structural category at all.
For this reason, comparisons between NAD+ and peptides are most useful when they focus on specific mechanisms, clinical outcomes, research quality, and regulatory status, rather than treating all compounds promoted in the context of longevity as interchangeable.
Comparison of the weight of evidence
The hierarchy of evidence varies significantly depending on the context and the specific claim.
Tesamorelin has strong data from randomised phase 3 trials for a narrow, clearly defined clinical indication and has undergone formal FDA evaluation for this use [3,4].
Its evidentiary base becomes considerably weaker when claims extend beyond HIV-associated lipodystrophy to general anti-ageing, longevity, or body composition in populations not represented in the key studies [8].
NAD+ precursors do not have a comparable approved indication, but they have been studied in a broader range of populations and outcomes.
This creates a different type of evidence base: broader and more exploratory, but less conclusive for a single medical indication.
Other research peptides may have an even narrower evidence base, depending on the specific compound.
The fact that NAD+, Tesamorelin, Sermorelin, Selank and other compounds appear together in longevity clinics or online discussions does not mean that the quality of the evidence supporting them is comparable.
Clinical evidence remains specific to the particular compound and the specific effect being evaluated.
Limitations of current evidence
- The strongest evidence regarding tesamorelin relates specifically to its FDA-approved indication, which is the reduction of excess visceral adipose tissue in adults with HIV-associated lipodystrophy. Evidence regarding off-label uses, such as general anti-ageing, effects on cognitive function, or body composition in individuals without HIV, is considerably less well established [8].
- No dedicated clinical studies have been identified testing NAD+ together with Tesamorelin, Sermorelin, or other peptides that are GHRH analogues.
- Research into NAD+ precursors covers a broader range of results than the narrow approved indication of Tesamorelin, but has not led to an FDA-approved medical indication for NAD+-related supplementation or therapy.
- It has been shown that the reduction in visceral adipose tissue observed during tesamorelin use reverses after treatment is stopped, meaning that the key evidence describes an effect associated with continued therapy rather than a permanent one-off change [3,4].
- The comparison concerns broad classes of compounds. Individual products, formulations and doses may differ significantly in terms of manufacturing standards, source, regulatory oversight and quality, particularly in the case of compounded preparations or peptides sourced from unregulated or less regulated channels outside the system of FDA-approved products.
Disclaimer
The article is strictly educational and summarises scientific research. It does not constitute medical advice or a recommendation for or against the use of NAD+, Tesamorelin, Sermorelin, Selank or any other peptide-based interventions.
NAD+ and its precursors should not be presented as FDA- or EMA-approved methods for the prevention, treatment or cure of diseases, unless referring to a specific approved medicinal product and indication.
Tesamorelin, sold under the brand names Egrifta and Egrifta WR, is approved by the FDA specifically for reducing excess visceral adipose tissue in adults with HIV-associated lipodystrophy. Uses beyond this approved indication are off-label and should not be presented as having the same level of evidence or the same regulatory status as the approved use. Grouping NAD+, Tesamorelin or other peptides in the same commercial longevity or biohacking category does not imply comparable mechanisms of action, efficacy, safety, regulatory status or quality of evidence.
References
[1] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[2] Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
[3] Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
[4] Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
[5] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomised, multicentre, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[6] Zhong, O., Wang, J., Tan, Y., Lei, X., & Tang, Z. (2022). Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: A meta-analysis. Nutrition & Metabolism, 19, 20. https://doi.org/10.1186/s12986-022-00653-9
[7] Falutz, J., Potvin, D., Mamputu, J. C., Assaad, H., Zoltowska, M., Michaud, S. E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomised placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322. https://doi.org/10.1097/QAI.0b013e3181cbdaff
[8] Sivakumar, T., Mechanic, O., Fehmie, D. A., & Paul, B. (2011). Growth hormone axis treatments for HIV-associated lipodystrophy: A systematic review of placebo-controlled trials. HIV Medicine, 12(8), 453–462. https://doi.org/10.1111/j.1468-1293.2010.00906.x